



1 FW  
1626

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO.:  
01662/50308

Application Number  
09/997,126

Filing Date  
November 29, 2001

Examiner  
Fiona Powers

Art Unit  
1626


Invention Title  
Novel Crystal Forms of Atorvastatin Hemi-Calcium  
and Processes for their Preparation as Well as Novel  
Processes for Preparing Other Forms

Inventor(s)  
ARONHIME et al.


Address to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: MAY 25, 2005

Signature: 

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. \*1.17(p) (submission of an information disclosure statement under \*1.97(c)) fee of \$180.00 and any additional fees that may be required to the deposit account of Kenyon & Kenyon, deposit account number 11-0600.
5. A duplicate copy of this communication is enclosed for charging purposes.

Dated: MAY 25, 2005 By: 

Joseph A. Coppola (Reg. No. 38,413)

CUSTOMER NUMBER 26646

KENYON & KENYON  
One Broadway  
New York, New York 10004-1050  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. 1662/50308	SERIAL NO. 09/997,126
	APPLICANT ARONHIME et al.	
	FILING DATE November 29, 2001	GROUP 1626

#### U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	6,528,661	March 4, 2003	Niddam et al.			

#### FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						NO

#### OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	K.L. Baumann et al., "The Convergent Synthesis of CI-981, an Optically Active, Highly Potent, Tissue Selective Inhibitor of HMG-CoA Reductase," Tetrahedron Letters, Vol. 33, No. 17 (1992) pp. 2283-2284
	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. ( 1996) pp. 879-881

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	